NCT07112196View on ClinicalTrials.gov

Visugromab in Cachexia International Trial

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

518

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
Cancer-associated Cachexia
Interventions
DRUG

Visugromab (CTL-002)

IV infusion

DRUG

Placebo

IV infusion

All Listed Sponsors
lead

CatalYm GmbH

INDUSTRY